Spit in a tube and, for about $100, uncover secrets and techniques held by your DNA. That was the promise of 23andMe, a direct-to-consumer genetic-testing firm. It proved well-liked—greater than 15m prospects coughed as much as obtain tailor-made reviews. Insights ranged from the banal (there’s a 48% likelihood you will have freckles) to the doubtless useful (you will have an elevated threat of type-2 diabetes). Finally, although, the enterprise was unprofitable. On March twenty third the agency filed for chapter.
